It inhibits not only free factor Xa with high selectivity but also prothrombinase bound and clot-associated factor Xa in a concentration-dependent manner.
It is a potent, selective direct inhibitor of factor Xa that is used in the prevention of venous thromboembolism (VTE) in adult patients after total hip replacement (THR) or total knee replacement (TKR) surgery.
For a 10 mg dose, the oral bioavailability of Rivaroxaban is high (80–100%) and is not affected by food intake.
The drug is metabolized to inactive metabolites in liver, half of which is excreted by kidneys and other half is excreted via faecal route.